Blincyto (blinatumomab) / Astellas, Amgen 
Welcome,         Profile    Billing    Logout  
 29 Diseases   78 Trials   78 Trials   3567 News 


«12...2021222324252627282930...4445»
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    [VIRTUAL] Optimal Timing of Blinatumomab for the Treatment of B-Lymphoblastic Leukemia () -  Sep 6, 2021 - Abstract #SOHO2021SOHO_379;    
    P3
    Promising results from small subsets of infants treated with blinatumomab provide hope that its addition to upfront therapy may at long last result in meaningful improvements in outcome.16 Additionally, exciting results from newly diagnosed Philadelphia chromosome positive B-ALL patients treated with only corticosteroids, dasatinib and blinatumomab hint at the possibility of ‘chemotherapy-free’ cures for certain patients.17 Conclusions Blinatumomab is a highly effective agent for the treatment of B-ALL. While it is a safe and efficacious treatment for relapsed or refractory patients with bulk or minimal residual disease, growing evidence supports its move into the upfront setting where its capacity to clear MRD appears to best translate into improved outcome.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Biomarker, Journal:  Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. (Pubmed Central) -  Sep 2, 2021   
    No examined biomarkers were significant for the risk of grade ≥3 adverse events. Incorporating baseline biomarkers into future studies may help to identify subgroups most likely to benefit from blinatumomab.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    ALLOIMMUNE CELLULAR AND HUMORAL MONITORING IN A KIDNEY TRANSPLANT RECIPIENT THAT PRESENTS AN ACUTE LEUKEMIA TREATED WITH BLINATUMOMAB (Room I - White 2) -  Aug 28, 2021 - Abstract #ESOT2021ESOT_535;    
    A 55-year-old man received a living KT (5 HLA mismatches), with basiliximab induction and maintenance therapy of tacrolimus, mycophenolate and steroids...Consolidation therapy was mercaptopurine, prednisone, vincristine and methotrexate...Rapamycin was reintroduced and prednisone adjusted...Strict monitoring of both humoral and cellular responses was performed to safely adapt the anti-rejection regimen during blinatumomab. A close immunomonitoring strategy at humoral but also at T-cell level translates an individualized improvement in graft and patient survival.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia. (Pubmed Central) -  Aug 1, 2021   
    Modified constructs with lower peak expansion or longer persistence provide better control of the toxicity and might improve the efficacy. Finally, the allogeneic "off the shelf" constructs from healthy donors avoid the time-consuming preparation and the exhaustion of immune cells.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    [VIRTUAL] Use of CAR -T Cells in Allogeneic Stem Cell Transplantation (CHANNEL A) -  Jul 31, 2021 - Abstract #ICBMT2021ICBMT_109;    
    Our data analysis per univ showed that TP53 mutation, bone marrow blasts > 20%, prior CAR-T/blinatumomab treatment and severe cytokine release syndrome (CRS) were associated with a lower complete remission (CR) rate while age, extramedullary disease, complex cytogenetics, history of prior transplant, prior courses of chemotherapy, CAR-T cell dose and manufacturing source of the cellular product did not affect patients’ CR rate...In conclusion, our study demonstrates that even for R/R B-ALL patients who relapsed after first allo-HSCT, MRD-negative CR status can still be achieved through CAR-T cell therapy, without increasing CRS or neurotoxicity. To improve duration of remission, CAR T-cell therapy followed by consolidation second allo-HSCT may be considered for selected young and fit patients.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, mosunetuzumab (BTCT4465A) / Roche
    [VIRTUAL] Novel Immunotherapeutic Approaches with Antibody Drugs (CHANNEL A) -  Jul 31, 2021 - Abstract #ICBMT2021ICBMT_95;    
    Actually, in patients with diffuse large B-cell lymphoma and with an median age of 82 and an age range up to 100 years received monotherapy with a bispecific antibody Mosunetuzumab targeting CD20 including patients with an impaired renal and impaired cardiac function. The studies also confirmed that in non-transplant eligible patients, therapy with bispecific antibodies can be performed either as front line ther- apy or as a kind of consolidation after tumor debulking.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    [VIRTUAL] The Role of Flow-, PCR- and NGS-based MRD in Guiding HCT and CAR T-cell Therapy for Acute Lymphoblastic Leukemia (CHANNEL B) -  Jul 31, 2021 - Abstract #ICBMT2021ICBMT_56;    
    Background: Children, adolescents, and young adults with high risk, relapsed or refractory acute lymphoblastic leukemia (ALL) require intensive therapies including hematopoietic cell transplantation, targeted immune therapy (blinatumomab/inotuzumab) and CAR T-cell therapies for cure. The use of MRD monitoring pre- and post-HCT and CAR T-cell treatment can define high and low risk patients that may benefit from withdrawal of immune suppression, HCT after CAR T-cell therapy, or other novel therapies aimed at preventing relapse.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    [VIRTUAL] Treatment Stratigies after Allogeneic HSCT in Relapsed ALL (CHANNEL A) -  Jul 31, 2021 - Abstract #ICBMT2021ICBMT_36;    
    But, there are very few well-designed studies in this area, except the BCR-ABL TKI for Ph+ALL. I will briefly review the results of these therapies such as, donor lymphocyte infusion, blinatumomab in MRD+ patients, immune checkpoint inhibitors, cytokines, immune cell therapy, and blinatumomab and inotuzumab maintenance therapy.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Clinical, Journal:  Nurse Practitioner Management of a Blinatumomab Infusion Program: Impact on Patient Safety and Quality of Care. (Pubmed Central) -  Jul 16, 2021   
    The purpose of this study is to describe the experience gained over 4 years in the management of pediatric patients undergoing therapy with blinatumomab in an Italian tertiary hospital. The establishment of a nursing program dedicated to improving infusion pump management, patient support, quality of care, and patient safety will be discussed.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Clinical, Journal:  Blinatumomab for HLA loss relapse after haploidentical hematopoietic stem cell transplantation. (Pubmed Central) -  Jul 13, 2021   
    By redirecting lysis of CD19-positive lymphoblast who losing the incompatible HLA, blinatumomab is a potential strategy to eradicate malignant cells via restoring GVL effects. A randomized clinical trial assessing blinatumomab in patients with HLA loss relapse after HSCT is warranted.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Clinical, Review, Journal:  Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review). (Pubmed Central) -  Jul 4, 2021   
    Due to the distinct pattern of adverse events compared to high-dose conventional chemotherapy, blinatumomab could play an important role for patients with a risk for severe chemotherapy-associated toxicities. This systematic review discusses all published results for blinatumomab in children as well as all ongoing clinical trials.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Preclinical, Journal, IO biomarker:  Concomitant use of a dual ABL/Src kinase inhibitor eliminates the in vitroefficacy of blinatumomab against Ph+ ALL. (Pubmed Central) -  Jul 4, 2021   
    Importantly, there was no loss of CD19+ cells treated with blinatumomab plus dasatinib or ponatinib in healthy samples as well as samples with a resistant ABL T315I mutation by dasatinib in combination with blinatumomab. These in vitro findings bring pause to the excitement of combination therapies highlighting the importance of maintaining T-cell function with targeted therapies.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Clinical, Journal:  Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. (Pubmed Central) -  Jul 4, 2021   
    Our analysis suggests that novel high-risk groups derive a similar benefit from allo-HCT as traditional high-risk adult ALL and that novel targeted therapies do not seem to independently predict for posttransplantation outcomes. It also calls for further exploration of maintenance strategies after Allo-HCT to prevent relapse in high-risk subgroups.